Hostname: page-component-cd9895bd7-hc48f Total loading time: 0 Render date: 2024-12-29T11:15:00.548Z Has data issue: false hasContentIssue false

Clozapine for the treatment of levodopa and dyskinesia in Parkinson's disease

Published online by Cambridge University Press:  13 June 2014

Gwyneth Rees
Affiliation:
The Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2QZ, England
Peter Madeley
Affiliation:
The Queen Elizabeth Psychiatric Hospital, Mindelsohn Way, Edgbaston, Birmingham B15 2QZ, England
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter
Copyright
Copyright © Cambridge University Press 1995

References

1.Hughes, TA, Mindham, RHS, Ross, HF. Clozapine for the treatment of levodopa -induced psychosis and dyskinesia in Parkinson's disease. Ir J Psychol Med 1995 12:39.CrossRefGoogle Scholar
2.Jalenques, I, Coudert, A-J. Clozapine for the treatment of levodopa - induced psychosis and dyskinesia in Parkinson's disease. Irish Journal of Psychological Medicine. 1995Google Scholar
3.Alessandra, M, Bonifeti, V, Giustini, P. Risperidone for hallucinations in levodopa -treated Parkinson's disease patients. Lancet 1994 343. 13701371Google Scholar
4.Lee, H, Cooney, JM, Lawlor, BA. The use of risperidone, an atypical neuroleptic, in Lewy body disease. International Journal of Geriatric Psychiatry. 1994 9: 415417.CrossRefGoogle Scholar
5.Madeley, P, Biggins, CA, Boyd, JL, Midham, RHS, Spokes, EGS. Cell implantation in Parkinson's disease. British Medical Journal 1990 301:556.CrossRefGoogle ScholarPubMed
6.Hurwitz, TA, Calne, DB, Waterman, K. Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. Can J Neurol Sci 1988 02; 15(1):32–4CrossRefGoogle ScholarPubMed